NFE2L2 and melanoma: An immunohistochemical/immunochemical study conducted on 255 samples obtained from 172 patients with different diagnoses of melanoma (nevi, primary melanomas, and melanoma metastases) showed how Nrf2 expression decreases very early in melanoma carcinogenesis process, while its expression levels increase from primary to metastatic lesions.